Abstract: Described herein are methods comprising the oral administration of budesonide for the treatment of ulcerative colitis and Crohn's colitis in its active phase. The methods can also be applied as relapse preventing therapy for Crohn's colitis in its chronic phase and Crohn's disease in the small intestine.

Abstract: A compound of the formula ##STR1## wherein R is --CH(CH.sub.3).sub.2 or --C(CH.sub.3).sub.3 or a physiologically acceptable salt or optical isomer thereof useful for the treatment of particularly different lung diseases.

Abstract: A compound of the formula ##STR1## wherein R is --CH(CH.sub.3).sub.2 or --C(CH.sub.3).sub.3 or a physiologically acceptable salt or optical isomer thereof useful for the treatment of particularly different lung diseases.

Abstract: The present invention refers to a device in connection with an inhaler intended for measuring and recording the course of inhalation of a patient. The device is intended for use in medication, e.g. clinical tests, where there is a need of afterwards being able to control if the patient has taken medicine in a prescribed way. The device comprises an electronic unit provided in the inhaler for recording of the time for each dosage of the medicine of the inhaler. A detector (16,32,36) is provided in the inhaler in connection with a passage for the airflow of inhalation, whereby the detector detects the airflow of the inhalation through the inhaler as well as the availability of the medicine at the inhalation within said passage, so that a combination of these two detected values decides if and how the performed inhalation should be recorded in the electronical unit (11,33,35).

Abstract: The invention refers to compounds having activity against inflammatory, allergic, and dermatological conditions. The compounds are characterized by the formula ##STR1## or a stereoisomeric component thereof, in which formula R.sub.1 is selected from a straight or branched hydrocarbon chain having 1-4 carbon atoms.The invention also refers to processes for the preparation of these compounds, pharmaceutical preparations containing one of the compounds and a method for the treatment of inflammatory, allergic, muscoskeletal and dermatological conditions.

Abstract: The invention refers to compounds having anti-inflamatory activity characterized by the formula ##STR1## or a stereoisomeric component thereof, in which formula the 1,2-position is saturated or is a double bondX.sub.1 is selected from hydrogen, fluorine, chlorine and bromineX.sub.2 is selected from hydrogen, fluorine, chlorine and bromineR.sub.1 is selected from hydrogen or a straight or branched hydrocarbon chain having 1-4 carbon atomsR.sub.2 is selected from hydrogen or straight and branched hydrocarbon chains having 1-10 carbon atoms andR.sub.3 is selected from ##STR2## is O or S R.sub.4 is selected from hydrogen, straight or branched hydrocarbon chains having 1-10 carbon atoms or from phenylR.sub.5 is selected from hydrogen or methyl andR.sub.

Abstract: Device in a previously known powder inhalator intended for inhalation of an air flow which contains pharmacologically active compound in micronized form. The powder inhalator comprises a nozzle unit (2) with a nozzle aperture (2a) as well as a container unit (3) with a releasing or dosing unit (6) for delivering the active compound. The air flow generated by inhalation is at least partly aspirated through an air conduit (7) located in the container unit (3), which conduit extends from an air inlet (8), communicating with the environment, via said releasing or dosing unit (6), up to said nozzle unit (2). According to the invention, deflector devices are stationarily arranged in the container unit (3) and/or in the nozzle unit (2), said deflector devices, for example in the shape of a helical channel portion (13), being arranged to create a powerful deflecting movement for the purpose of disrupting said powder particles into the respirable particle size distribution (less than 5 .mu.m).

Abstract: The invention refers to compounds having anti-inflammatory activity, characterized by the formula ##STR1## in the form of a stereoisomeric mixture or an epimer of the R or S type regarding the orientation of the substituents in the carbon atom at position 20, in which formula the 1,2 position is saturated or is a double bond,X.sub.1 is hydrogen, fluorine, chlorine or bromine,X.sub.2 is hydrogen, fluorine, chlorine or bromine,R.sub.1 is hydrogen or methyl,R.sub.2 is a straight or branched hydrocarbon chain having 1-10 carbon atoms andR.sub.3 is hydrogen or a straight or branched chain alkyl group having 1-12 carbon atoms, a lower alkyl group substituted by 1-5 halogen atoms or an unsubstituted or substituted phenyl or benzyl group,provided that when R.sub.1 is methyl R.sub.2 is a hydrocarbon chain having 2-10 carbon atoms.

Abstract: A dosage device for dosing with high accuracy a particulate material containing a pharmacologically active substance, including a storage chamber, a rotatable dosing unit adjacent the storage chamber, and an operating unit to cause relative rotation between the dosing unit and the storage chamber. The dosing unit is provided with a plurality of upwardly opening recesses opening into said storage chamber to receive particulate material therefrom through an outlet opening from the storage chamber. Scrapers are positioned in the outlet opening immediately above these recesses to pack and level the particulate material into the recesses and level the material off with the upper surface of the dosing unit as the dosing unit rotates relative to the storage chamber.

Abstract: A method for the treatment of chronic obstructive airway disease or cardiac disease, characterized by the administration of a compound of the formula ##STR1## wherein R is n-propyl, n-butyl or isobutyl or a therapeutically acceptable salt thereof.

Abstract: The invention refers to compounds having anti-inflammatory activity characterized by the formula ##STR1## or a stereoisomeric component thereof, in which formula X.sub.1 represents a hydrogen, chlorine, bromine or fluorine atom;X.sub.2 represents a hydrogen, chlorine, bromine or fluorine atom;R.sub.1 represents a .beta.-hydroxy group, a .beta.-chlorine atom or an oxo group;R.sub.2 represents a hydrogen atom, a methylene group or an .alpha.- or .beta.-methyl group;R.sub.3 represents a hydrogen atom or an acyl group of 1 through 8 carbon atoms;R.sub.4 represents a hydrogen atom, a (C.sub.1 -C.sub.5) alkyl group or a phenyl group;R.sub.5 represents a hydrogen atom, a (C.sub.1 -C.sub.5) alkyl group or a phenyl group;Y represents either CR.sub.7 R.sub.8, O, S or NR.sub.9, where R.sub.7, R.sub.8 and R.sub.9 are selected from hydrogen or from straight or branched hydrocarbon chains having 1-8 carbon atoms or from a phenyl group.R.sub.

Abstract: A dosage package of a thermoplastic material with a relatively flat container (1), which has a permanently shaped edge wall portion (5) extending all around, as well as two opposite side wall portions (8,9), which are compressable to discharge a well defined dosage via a discharge tube (), which is connected to the edge wall portion (5).

Abstract: A method for the preparation of enprofylline is disclosed, which method comprises(a) treating 6-amino-1-n-propyl-2,4-(1H,3H)-pyrimidinedione in formic acid with sodium nitrite in the presence of a catalyst to the formation of 6-amino-5-formamido-1-n-propyl-2,4-(1H,3H)-pyrimidinedione and(b) performing a ring-closure reaction on the formed 6-amino-5-formamido-1-n-propyl-2,4-(1H,3H)-pyrimidinedione to the formation of 3,7-dihydro-3-n-propyl-1H-purin-2,6-dione.

Abstract: Pharmaceutical composition for administration primarily to the respiratory tract when treating and controlling anti-inflammatory conditions comprising liposomes in combination with a compound of the formula ##STR1## and R.sup.1 is a saturated or unsaturated, straight or branched alkyl group with 11-19 carbon atoms and R is H, --COCH.sub.3, --COC.sub.2 H.sub.5, --CO(CH.sub.2).sub.2 CH.sub.3 or --CO(CH.sub.2).sub.3 CH.sub.3.The invention also refers to the compounds of the formula I per se processes for preparation of these compounds and to a method for the treatment of inflammatory conditions.

Abstract: A dosage inhalator for the inhalation of a pharmacologically active compound in solution form is disclosed. The inhalator comprises a propellant container, a propellant dispensing unit, and a dosing unit for dosing the pharmacologically active compound. The dosing unit comprises a storage chamber for the active compound, a dose loading unit directly connected thereto, and a nozzle. The does loading unit comprises a movable perforated membrane, and a holder for the perforated membrane. The membrane is displaceable between a first position where a solution of active compound is introduced into the perforations of the membrane, and second position where the perforations of the membrane are inserted into a propellant passage.

Abstract: An indicating means in a dosage dispensing device for medicaments, particularly a dosage inhaler which indicates a number of dosages administered from the dosage dispensing device. The indicating means includes a rotatable disc (1) having apertures (2) passing therethrough which can be filled with a medicament in particle form. By rotating the disc the apertures can be brought into an air channel or duct (3) through which air is inhaled. The rotatable disc has associated with a central portion a spiral groove or ridge (4) which can engage with peripheral teeth (8) on a toothed wheel (6), such that rotation of the disc (1) results in rotation of the toothed wheel and the toothed wheel is provided with one or more markings (9) which are visible from outside the dosage inhaler upon rotating the disc a predetermined number of times.

Abstract: Compounds having activity against chronic obstructive airway disease or cardiac disease, characterized by the formula ##STR1## wherein R.sup.1 is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R.sup.2 is hydrogen or methyl, provided that R.sup.2 is methyl when R.sup.1 is n-propyl, n-butyl or isobutyl, or a physiologically acceptable salt thereof.

Abstract: An aerosol inhalation device in pocket-size which has one dosage dispensing position and one storage position, and which comprises a two-part telescoping deceleration chamber (2, 3) with rectangular cross-section and a socket (1) for an exchangeable aerosol container. The socket is connected with the inner chamber part (2) so that it can be telescopically inserted therein to form a storage position. In dosage dispensing position the socket is extended from the deceleration chamber, pivoted at an angle relative to the longitudinal axis of the chamber and locked in the angle.

Abstract: The invention refers to compounds having activity against chronic obstructive airway disease or cardiovascular disease, characterized by the formula ##STR1## wherein R.sup.1 is ethyl, n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R.sup.2 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert. butyl, or cyclobutyl provided that R.sup.1 is ethyl when R.sup.2 is methyl, or a physiologically acceptable salt thereof. The invention also refers to processes for the preparation of these compounds, a pharmaceutical preparation containing one of the compounds and a method for the treatment of chronic obstructive airway disease and cardiovascular disease.

Abstract: A dosage inhalator for the inhalation of a pharmacologically active compound in solid, micronized form is disclosed. The inhalator comprises a propellant container, a propellant dispensing unit, and a dosing unit for dosing the pharmacologically active compound. The dosing unit comprises a storage chamber for the active compound, a dose loading unit directly connected thereto, and a nozzle. The dose loading unit comprises a movable perforated membrane, and a holder for the perforated membrane. The membrane is displaceable between a first position where active compound is introduced into the perforations of the membrane, and second position where the perforations of the membrane are inserted into a propellant passage. While the membrane is in the second position, the propellant dispensing unit may be operated, allowing propellant originally stored in the propellant container to remove the active compound from the perforations inserted into the propellant passage and carry said compound out the nozzle.